de Lorenzo A, Ceccanti M, Assogna G, Romeo M, Cavaleri G, Attilia M L
National Council of Research, Rome, Italy.
Int J Clin Pharmacol Res. 1988;8(5):321-5.
In a randomized double-blind trial involving 40 alcoholic hypertensive patients, the antihypertensive activity of ketanserin, a serotonin antagonist with high affinity for S2 serotonergic receptors, was compared with a placebo. Patients in both groups were matched for age, body weight, blood pressure, alcoholic consumption, and length of alcoholism. The administration of ketanserin significantly reduced (p less than 0.001) mean supine blood pressure from 167/106 mmHg (22.3/14.1 kPa) at baseline to 145/87 mmHg (19.3/11.6 kPa) after 90 days of treatment versus a slight non-significant reduction with the placebo. No significant changes in heart rate, body weight, or laboratory parameters occurred. The incidence of side-effects was low in both groups. The results of this study suggest the possible role of serotonin in the pathogenesis of alcohol-related hypertension and the potential treatment of the disease using S2-receptor antagonists such as ketanserin.
在一项涉及40名酒精性高血压患者的随机双盲试验中，将对S2血清素能受体具有高亲和力的血清素拮抗剂酮色林的降压活性与安慰剂进行了比较。两组患者在年龄、体重、血压、酒精摄入量和酗酒时间方面相匹配。酮色林治疗显著降低了（p<0.001）平均仰卧血压，从基线时的167/106 mmHg（22.3/14.1 kPa）降至治疗90天后的145/87 mmHg（19.3/11.6 kPa），而安慰剂组仅有轻微的、无统计学意义的降低。心率、体重或实验室参数均无显著变化。两组的副作用发生率都很低。本研究结果提示血清素在酒精相关性高血压发病机制中可能发挥的作用，以及使用酮色林等S2受体拮抗剂治疗该疾病的潜在可能性。
